CL2021003047A1 - Forma cristalina de bromuro de sofpironio y método para su preparación - Google Patents

Forma cristalina de bromuro de sofpironio y método para su preparación

Info

Publication number
CL2021003047A1
CL2021003047A1 CL2021003047A CL2021003047A CL2021003047A1 CL 2021003047 A1 CL2021003047 A1 CL 2021003047A1 CL 2021003047 A CL2021003047 A CL 2021003047A CL 2021003047 A CL2021003047 A CL 2021003047A CL 2021003047 A1 CL2021003047 A1 CL 2021003047A1
Authority
CL
Chile
Prior art keywords
sophironium
bromide
crystalline form
preparation
diastereomer
Prior art date
Application number
CL2021003047A
Other languages
English (en)
Inventor
Kazuyoshi MARUBAYASHI
Masahito Watanabe
Herbert R Brinkman
Original Assignee
Kaken Pharma Co Ltd
Brickell Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd, Brickell Biotech Inc filed Critical Kaken Pharma Co Ltd
Publication of CL2021003047A1 publication Critical patent/CL2021003047A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/147—Saturated compounds having only one carboxyl group and containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporciona un cocristal que contiene el diastereómero 1'R y el diastereómero 1'S de bromuro de sofpironio en una relación de 1:3 (Forma CO), una mezcla de cristales (por ejemplo, la Forma B) que contiene la Forma CO y una forma cristalina del diastereómero 1'R (Forma MN), y un método para preparar bromuro de sofpironio, que es adecuado para la fabricación de la mezcla de cristales. La Forma CO y una forma cristalina de bromuro de sofpironio que contiene la Forma CO (por ejemplo, la Forma B) tienen una estabilidad superior sin propiedades higroscópicas y, por consiguiente, pueden usarse preferentemente como materia prima de medicamentos.
CL2021003047A 2019-05-23 2021-11-18 Forma cristalina de bromuro de sofpironio y método para su preparación CL2021003047A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962851880P 2019-05-23 2019-05-23

Publications (1)

Publication Number Publication Date
CL2021003047A1 true CL2021003047A1 (es) 2022-09-20

Family

ID=72146250

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003047A CL2021003047A1 (es) 2019-05-23 2021-11-18 Forma cristalina de bromuro de sofpironio y método para su preparación

Country Status (16)

Country Link
US (3) US20220298108A1 (es)
EP (1) EP3972955A4 (es)
JP (2) JP6748329B1 (es)
KR (1) KR20220011671A (es)
CN (1) CN114008023B (es)
AU (1) AU2020277881A1 (es)
BR (1) BR112021023241A2 (es)
CA (1) CA3139948A1 (es)
CL (1) CL2021003047A1 (es)
CO (1) CO2021017456A2 (es)
IL (1) IL288285A (es)
MX (1) MX2021014163A (es)
SG (1) SG11202111678WA (es)
TW (2) TWI838531B (es)
WO (1) WO2020235665A1 (es)
ZA (1) ZA202109514B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4002383A3 (en) 2020-11-13 2022-08-03 Tokyo Institute of Technology Information processing device, information processing method, recording medium recording information processing program, and information processing system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
JP5257073B2 (ja) * 2005-11-10 2013-08-07 ボーダー、ニコラス・エス ソフト型抗コリン作動性エステル
US7399861B2 (en) * 2005-11-10 2008-07-15 Bodor Nicholas S Soft anticholinergic esters
MX357741B (es) * 2012-07-06 2018-07-23 Laboratorios Senosiain S A De C V Star Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5.
US9512166B2 (en) * 2012-09-05 2016-12-06 Amri Ssci, Llc Cocrystals of progesterone
US20150259283A1 (en) * 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
US10906871B2 (en) * 2016-08-02 2021-02-02 Dermira, Inc. Processes for making, and methods of using, glycopyrronium compounds

Also Published As

Publication number Publication date
WO2020235665A1 (en) 2020-11-26
CA3139948A1 (en) 2020-11-26
US20210395197A1 (en) 2021-12-23
US11566000B2 (en) 2023-01-31
TW202411205A (zh) 2024-03-16
JP2020189856A (ja) 2020-11-26
IL288285A (en) 2022-01-01
EP3972955A4 (en) 2023-07-05
ZA202109514B (en) 2023-12-20
JP2020189839A (ja) 2020-11-26
AU2020277881A1 (en) 2021-12-09
SG11202111678WA (en) 2021-11-29
TWI838531B (zh) 2024-04-11
CN114008023A (zh) 2022-02-01
MX2021014163A (es) 2022-01-04
CO2021017456A2 (es) 2022-01-17
US20220298108A1 (en) 2022-09-22
JP6748329B1 (ja) 2020-08-26
US20210171460A1 (en) 2021-06-10
TW202110796A (zh) 2021-03-16
EP3972955A1 (en) 2022-03-30
BR112021023241A2 (pt) 2022-01-04
KR20220011671A (ko) 2022-01-28
CN114008023B (zh) 2024-02-09
US11584715B2 (en) 2023-02-21

Similar Documents

Publication Publication Date Title
CR20210504A (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
CY1123689T1 (el) Κρυσταλλικη μορφη ελευθερης βασης λορλατινιβης
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
AR113782A1 (es) Preparación y almacenamiento de formulaciones de arn liposomal adecuadas para tratamiento
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
MX2019015744A (es) Composiciones farmaceuticas.
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
BR112017004448A2 (pt) uso de agente de reforço de receptor gabaa na preparação de medicamento sedativo e anestésico
AR071788A1 (es) Derivados de 3-aminocarbazol, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos para tratar y/o prevenir trastornos asociados con la produccion de prostaglandina e2(pge2), tales como aterosclerosis, artritis, artrosis y tumores, entre otros.
PH12018500377A1 (en) Novel annelated benzamides
CY1126141T1 (el) Κρυσταλλικη μορφη του υδριτη ελευθερης βασης λορλατινιμπης
UY36651A (es) Compuestos antiestrogénicos
AR068187A1 (es) Forma cristalina de un intermediario sintetico para la preparacion de un inhibidor de dpp-iv
AR083484A1 (es) Mezcla de fosfato para fabricar un cemento de alta resistencia, composicion, suspension de cemento y metodo para fabricar un producto cementoso
UY34854A (es) Inhibidores del transporte de glucosa
MX2018009500A (es) Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus metodos de preparacion y usos de la sal de maleato y formas cristalinas.
MY194711A (en) Novel annelated phenoxyacetamides
CL2021003047A1 (es) Forma cristalina de bromuro de sofpironio y método para su preparación
PH12019500681A1 (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
PE20141049A1 (es) Composicion farmaceutica antihipertensiva
WO2018125880A8 (en) Nrf2 activator
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
MX2018001735A (es) Compuestos espirocíclicos de fumagillol y compuestos bicíclicos fusionados y métodos de elaboración y uso de los mismos.
MX2016004963A (es) Sal y formas cristalinas de inhibidores de quinasa tipo polo-4.